BioSyent Inc. (TSXV:RX)
15.31
+0.11 (0.72%)
At close: Mar 18, 2026
BioSyent Balance Sheet
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 16.57 | 12.11 | 7.98 | 7.86 | 18.04 | 20.29 |
Short-Term Investments | 6.83 | 3.83 | 18.2 | 20.83 | 10.18 | 5.29 |
Cash & Short-Term Investments | 23.4 | 15.94 | 26.19 | 28.7 | 28.21 | 25.58 |
Cash Growth | 37.10% | -39.13% | -8.74% | 1.72% | 10.30% | 16.40% |
Accounts Receivable | 6.28 | 2.91 | 3.48 | 3.5 | 2.79 | 1.82 |
Other Receivables | 0.06 | 0.09 | 0.07 | 0.16 | 0.42 | - |
Total Trade Receivables | 6.33 | 2.99 | 3.55 | 3.66 | 3.21 | 1.82 |
Inventory | 5.9 | 5.33 | 5.89 | 4.54 | 2.2 | 2.07 |
Other Current Assets | 0.34 | 0.21 | 0.24 | 0.25 | 0.46 | 0.31 |
Total Current Assets | 35.97 | 24.47 | 35.87 | 37.14 | 34.08 | 29.77 |
Net Property, Plant & Equipment | 1.04 | 1.2 | 1.44 | 1.67 | 1.93 | 2.16 |
Other Intangible Assets | 4.95 | 5.04 | 1.15 | 1.2 | 0.87 | 1.01 |
Long-Term Investments | 5.48 | 10.24 | 2.71 | 0.26 | 0.18 | 0.6 |
Other Long-Term Assets | 0.34 | 0.4 | 0.36 | 0.21 | 0.1 | 0.03 |
Total Assets | 47.79 | 41.36 | 41.53 | 40.49 | 37.17 | 33.57 |
Accounts Payable | 6.41 | 4 | 5.08 | 5.06 | 3.56 | 3.72 |
Current Portion of Leases | 0.21 | 0.2 | 0.18 | 0.17 | 0.16 | 0.15 |
Unearned Revenue | 0.16 | 0.81 | 0.13 | 0.16 | 0.31 | 0.93 |
Other Current Liabilities | 0.33 | 0.4 | 0.14 | 0.32 | 0.1 | 0.33 |
Total Current Liabilities | 7.11 | 5.41 | 5.53 | 5.72 | 4.14 | 5.14 |
Long-Term Leases | 0.68 | 0.84 | 1.04 | 1.22 | 1.4 | 1.56 |
Other Long-Term Liabilities | 0.09 | 0.11 | 0.2 | 0.18 | 0.08 | 0.08 |
Total Long-Term Liabilities | 0.78 | 0.95 | 1.24 | 1.4 | 1.48 | 1.64 |
Total Liabilities | 7.88 | 6.36 | 6.77 | 7.12 | 5.61 | 6.78 |
Common Stock | 5.24 | 5.31 | 5.12 | 5.37 | 5.8 | 6.39 |
Additional Paid-in Capital | 2.01 | 2.14 | 2.29 | 2.23 | 1.82 | 1.49 |
Accumulated Other Comprehensive Income | -0.17 | -0.17 | -0.18 | -0.14 | -0.19 | -0.17 |
Retained Earnings | 32.82 | 27.73 | 27.53 | 25.91 | 24.12 | 19.08 |
Shareholders' Equity | 39.9 | 35 | 34.76 | 33.36 | 31.55 | 26.8 |
Total Liabilities & Equity | 47.79 | 41.36 | 41.53 | 40.49 | 37.17 | 33.57 |
Total Debt | 0.89 | 1.04 | 1.22 | 1.4 | 1.56 | 1.71 |
Net Cash (Debt) | 22.5 | 14.9 | 24.97 | 27.3 | 26.65 | 23.87 |
Net Cash Growth | 50.99% | -40.31% | -8.55% | 2.42% | 11.67% | 18.63% |
Net Cash Per Share | 1.95 | 1.26 | 2.05 | 2.18 | 2.07 | 1.82 |
Book Value | 39.9 | 35 | 34.76 | 33.36 | 31.55 | 26.8 |
Book Value Per Share | 3.45 | 2.96 | 2.86 | 2.66 | 2.45 | 2.05 |
Tangible Book Value | 34.95 | 29.96 | 33.61 | 32.16 | 30.68 | 25.79 |
Tangible Book Value Per Share | 3.02 | 2.54 | 2.76 | 2.56 | 2.38 | 1.97 |
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.